Followers | 177 |
Posts | 24473 |
Boards Moderated | 12 |
Alias Born | 04/03/2002 |
Wednesday, April 05, 2023 3:51:02 PM
From the news:
Vered Caplan, CEO of Orgenesis, said, “I am pleased to report that revenue for the fourth quarter of 2022 increased by 98% to $13.6 million, compared to $6.9 million for the same period last year as we are progressing with the planned rollout of our POCare platform. In addition to our strong revenue growth, we reduced our operating loss by 91% for the fourth quarter of 2022 versus the same period last year, which reflects our cost-effective and highly scalable business model. The goal of our Orgenesis Mobile Processing Units and Labs (OMPUL) strategy is to provide autologous cell and gene therapies to patients in need at the point-of-care, which, in turn, is expected to dramatically lower costs. Our latest investments have allowed us to increase our capacity and advance our go-to-market strategy as we aim to expand the deployment of our Orgenesis Mobile Processing Units and Labs (OMPULs). Most recently, we signed a non-binding memorandum of understanding (MOU) with University of California, Davis (UC Davis) to deploy our OMPULs at UC Davis and other healthcare universities within the State of California. Additionally, we are focused on supporting the POCare Centers located at strategic locations in various countries across North America, Europe, Asia, and the Middle East, which serve as hubs for the respective regions.”
Ms. Caplan continued, “Orgenesis is also advancing our POCare therapeutic pipeline, while leveraging grants and partnerships. In 2022, our subsidiary, Koligo Therapeutics, supplied Kyslecel to five medical institutes supplying total pancreatectomy - islet auto transplant (TP-IAT) cases. Production from this one site enabled Koligo to achieve positive cash flow from operations in the fourth quarter of the year as a separate business unit. Additionally, Koligo passed an FDA inspection of this site as a registered tissue production establishment in February. Following this confirmation of the infrastructure design and production protocols, and building on increasing demand, we are now pursuing plans for site expansion in the US and internationally. In the EU, Koligo is utilizing the expertise of Orgenesis to enable regional production capacity and leverage grants to drive clinical development towards marketing approval.”
The complete financial results for the fourth quarter and year ended December 31, 2022 are available on the Company’s website in the Company’s Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission.
Recent ORGS News
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 05/06/2024 07:30:18 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/06/2024 07:28:32 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 05/06/2024 07:26:43 PM
- Orgenesis Provides Year End Business Update • GlobeNewswire Inc. • 04/15/2024 09:07:16 PM
- Germfree and Orgenesis Announce Asset Purchase and Strategic Partnership Intended to Revolutionize Cell and Gene Therapy Through Decentralized Production and Global Accessibility • GlobeNewswire Inc. • 04/10/2024 04:00:00 PM
- Vered Caplan, CEO of Orgenesis, to Present at the Bioprocessing Summit Europe Conference • GlobeNewswire Inc. • 03/18/2024 12:30:00 PM
- Orgenesis Consortium Awarded €1.5M EUR Grant from the Walloon Government in Belgium for EXOFASTTRACK Project Dedicated to Accelerated Development of Multiple Therapeutic Exosomes • GlobeNewswire Inc. • 03/13/2024 12:30:00 PM
- Orgenesis Inc. Announces $2.3 Million Private Placement • GlobeNewswire Inc. • 03/04/2024 01:30:00 PM
- Orgenesis Consortium Awarded €2.0M EUR Grant from Walloon Government in Belgium for MAIDAM AI Project for Monitoring Decentralized ATMP Manufacturing • GlobeNewswire Inc. • 02/29/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/31/2024 02:20:12 PM
- Orgenesis Acquires Control of Octomera with the Goal of Progressing its Decentralized Immuno-Oncology Portfolio to Clinic • GlobeNewswire Inc. • 01/31/2024 02:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/24/2024 09:05:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2024 09:01:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/08/2024 10:37:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/05/2024 11:02:39 AM
- Orgenesis Ranked No. 171st Fastest-Growing Company in North America on the 2023 Deloitte Technology Fast 500 TM • GlobeNewswire Inc. • 11/14/2023 01:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 09:15:50 PM
- Orgenesis Provides Business Update for the Third Quarter of 2023 • GlobeNewswire Inc. • 11/13/2023 09:15:50 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/09/2023 12:41:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/08/2023 02:24:05 PM
- Orgenesis Inc. Announces Pricing of $1.1 Million Registered Direct Offering • GlobeNewswire Inc. • 11/08/2023 02:00:10 PM
- Orgenesis Announces Expanded Partnership Between Octomera and UC Davis Through CIRM Grant Funding • GlobeNewswire Inc. • 11/02/2023 12:00:00 PM
- Orgenesis Announces Withdrawal of Proposed Public Offering • GlobeNewswire Inc. • 10/31/2023 01:30:00 AM
- Orgenesis Announces Proposed Underwritten Public Offering • GlobeNewswire Inc. • 10/30/2023 08:07:26 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM